Researchers from Wake Forest University School of Medicine, Winston-Salem, NC, and the University of Wisconsin, Madison, have confirmed their earlier findings that men who have too much calcium in their bloodstream subsequently have an increased risk of fatal prostate cancer, but they have also identified an even more accurate biomarker: high levels of ionized serum calcium.
Researchers from Wake Forest University School of Medicine, Winston-Salem, NC, and the University of Wisconsin, Madison, have confirmed their earlier findings that men who have too much calcium in their bloodstream subsequently have an increased risk of fatal prostate cancer, but they have also identified an even more accurate biomarker: high levels of ionized serum calcium.
The research was published in Cancer Epidemiology, Biomarkers & Prevention (2009; 18:575-8).
“Scientists have known for many years that most prostate cancers are slow-growing and that many men will die with, rather than of, their prostate cancer,” said senior author Gary G. Schwartz, PhD, of Wake Forest. “The problem is, how can we determine which cancers pose a significant threat to life and need aggressive treatment versus those that, if left alone, are unlikely to threaten the patient’s life? These findings may shed light on that problem.”
The team found that men in the highest third of ionized serum calcium levels are three times more likely to die of prostate cancer than are those with the least amount. They also confirmed a previous finding of a doubling of risk for fatal prostate cancer among men whose level of total serum calcium falls in the highest third of the total serum calcium distribution.
“These new findings, if confirmed, suggest that men in the lower end of the normal distribution of ionized serum calcium are three times less likely than men in the upper distribution to develop fatal disease,” Dr. Schwartz said. “These men may choose to delay treatment or perhaps defer it altogether. It also suggests that medicine may be able to help in lowering the risk of fatal prostate cancer by reducing serum calcium levels.”
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.